Global Hemoglobin A1c Testing Devices Market - 2024-2031

Global Hemoglobin A1c Testing Devices Market - 2024-2031

Global Hemoglobin A1c Testing Devices Market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031

The hemoglobin A1c testing devices measures the percentage of hemoglobin A in the blood with glucose attached. This test is crucial for monitoring blood glucose levels, as it helps determine if the body can produce enough insulin or if the cells can accept it. If blood glucose levels rise too high, it can lead to diabetes, a serious disease that can damage organs if not controlled.

The test measures the percentage of hemoglobin A attached to glucose compared to the total amount of hemoglobin A in the blood. A high hemoglobin A1c percentage indicates an increase in glucose levels in the blood, indicating a high average blood glucose level in the previous months.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of diabetes

As the number of people with diabetes rises worldwide, there is a greater need than ever for routine blood glucose monitoring, which in turn fuels the market for hemoglobin A1C testing equipment. For instance, according to WHO, about 422 million people worldwide have diabetes, the majority living in low-and middle-income countries, and 1.5 million deaths are directly attributed to diabetes each year. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few decades.

Furthermore, global hemoglobin A1c testing devices are also driven by various other factors like a rise in the advancements in the devices, a rise in the prevalence of chronic diseases and others helping the market to grow during the forecast period.

High costs associated with the testing devices

The global hemoglobin A1c testing devices market is hindered by various factors due to high test costs, time-consuming procedures, and low adoption in emerging economies. This is due to the high cost of laboratory testing and the preference of healthcare practitioners for blood glucose testing in emergencies. The lack of awareness and acceptance of this testing method by the healthcare fraternity and general population is also contributing to its low acceptance.

Segment Analysis

The global hemoglobin A1c testing devices market is segmented based on product type, technology, end-user and region.

The handheld devices from the product type segment accounted for approximately 54.3% of the Hemoglobin A1c Testing Devices market share

The handheld devices from the product type segment accounted for approximately 54.3%. Point-of-care (POC) HbA1c can provide rapid “on-site” results using handheld devices and blood samples obtained by fingerstick. The device requires little expertise and is easy to operate with no major procedural challenges. Some studies have proven that it can be used to facilitate the identification of prediabetes and diabetes, especially in resource-limited settings, at a relatively lower cost.

For instance, in May 2022, Labcorp, a global life sciences company launched an at-home collection kit called Labcorp OnDemand, which measures hemoglobin A1c from a small blood sample, making diabetes screening easier for millions of individuals.

Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like rapidly increasing incidence and prevalence of diabetic patients, coupled with a rise in healthcare expenditure. This indicates a greater utilization of diabetes care products in the country. Additionally, the availability of reimbursements has further fueled market expansion in the United States. Also, novel product launches by key players, FDA approvals and others help the overall region to have the highest market share during the forecast period.

For instance, in January 2024, The Food and Drug Administration (FDA) cleared Qvin’s Q-Pad A1c Test System to measure hemoglobin A1c (HbA1c) using menstrual blood in patients with diabetes.

The system consists of the Q-Pad Kit and the Q-Pad A1c Test. The kit is intended for the collection of menstrual blood samples by individuals 18 years of age and older using the Q-Pad, an unscented menstrual pad with an embedded blood collection strip (Q-Strip). Each kit includes 2 Q-Pads, a return sample container, and a stamped mailing pouch.

Covid 19 Impact Analysis

The COVID-19 pandemic had a significant impact on the market where continuous glucose monitoring and telemedicine have been crucial, even allowing for improvements in HbA1c results. During the lockdown, patients with better metabolic control were managed in the laboratory whereas patients with poorer control or a severe clinical situation were attended in diabetes units by POCT.

Adults returned to pre-pandemic management slowly because they were more susceptible to morbidity and mortality due to COVID-19. Coordination among all health professionals has been essential to offering the best management, especially in difficult scenarios such as the COVID-19 pandemic.

Market Segmentation

By Device Type
• Handheld Devices
• Bench-Top Devices

By Technology
• Boronate Affinity Chromatography
• Immunoassay
• Ion-exchange High-performance Liquid Chromatography (HPLC)
• Direct Enzymatic Assay
• Others

By End-Users
• Hospitals
• Clinics
• Laboratories
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Bio-Rad Laboratories, Inc., Abbott Laboratories, A.Menarini Diagnostics Ltd., Roche Diagnostics, Diazyme Laboratories, Inc., EKF Diagnostics Holdings Plc, PTS Diagnostics, Siemens Healthineers, ARKRAY Inc., Meril Life Sciences Pvt. Ltd and among others.

Key Developments

 In April 2023, Seoul, South Korea–based Orange Biomed operates out of Research Triangle Park, North Carolina in the U.S. The company currently has ongoing studies for its OBM rapid A1c test. It designed the glycated haemoglobin analyser to function through single-cell analysis of red blood cells.

 In August 2022, Precision Diabetes, Inc. and DxGen Corp. stated that they have entered into an exclusive agreement in the U.S. to launch Epithod AutoDx, a fully automatic point-of-care (POC) analyser that measures a comprehensive profile of diabetes tests. The initial test menu will begin with hemoglobin A1c (A1C), C-reactive protein, and urinary albumin, with additional diabetes tests to be added shortly.

Why Purchase the Report??
• To visualize the global hemoglobin A1c testing devices market segmentation based on product type, technology, application, usability, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of the hemoglobin A1c testing devices market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global hemoglobin A1c testing devices market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies